Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;37(6):1585-1588.
doi: 10.1007/s11606-022-07443-2. Epub 2022 Feb 22.

Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2

Mayssam Nehme  1 , Olivia Braillard  2 , Julien Salamun  2 , Frédérique Jacquerioz  2   3   4 , Delphine S Courvoisier  5   6 , Hervé Spechbach  2 , Idris Guessous  2   7
Affiliations

Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2

Mayssam Nehme et al. J Gen Intern Med. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have a conflict of interest.

Figures

Fig. 1
Fig. 1
Associations between vaccination and the post-acute sequelae of SARS-CoV-2 infection, stratified by age groups and sex (n = 1596). Post-acute sequelae of SARS-CoV-2 were defined as the presence of fatigue, difficulty concentrating or memory loss, loss of or change in smell, loss of or change in taste, shortness of breath, and headache. These six cardinal symptoms were chosen to characterize persistent symptoms in long-COVID patients based on previous studies on the prevalence of symptoms more than 6 months after an infection. Participants answering (“Prefer not to answer”) were not included in this analysis (n = 8). Participants reporting never having symptoms were not included in this analysis of post-acute sequelae of SARS-CoV-2. Participants received the COVID-19 vaccine (mRNA-1273) of Moderna in 60.7% of cases, and the Comirnaty® (BNT162b2) vaccine of Pfizer/BioNTech in 38.5% of cases. Participants answered the survey on average 250.3 ± 72.1 days from their infection (257.8 ± 70.9 days for vaccinated versus 243.2 ± 72.5 days for non-vaccinated) and on average 40.3 ± 29.2 days after vaccination (range from 0 to 183 days, median 37 days, IQR 19–57). OR: odds ratios; CI: confidence interval. Odds ratios were adjusted for time for infection, age, sex, smoking, and the following comorbidities present prior to the infection: overweight or obese, hypertension, respiratory disease, cardiovascular disease, diabetes, migraine, tension headache, sleeping disorder, anxiety, depression, hypothyroidism, anemia, and chronic fatigue.
See this image and copyright information in PMC

References

    1. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I. Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting. Ann Intern Med. 2021. doi: 10.7326/M21-0878. - PMC - PubMed
    1. Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series. Ann Intern Med. 2021:M21-1976. 10.7326/M21-1976. - PMC - PubMed
    1. LongCovidSOS, The impact of COVID vaccination on symptoms of Long Covid. An international survey of 900 people with lived experience https://3ca26cd7-266e-4609-b25f-6f3d1497c4cf.filesusr.com/ugd/8bd4fe_a33.... Accessed July 18, 2021. - PMC - PubMed
    1. Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, Lartey S, Onyango TB, Kuwelker K, Sævik M, Bartsch H, Tøndel C, Kittang BR; Bergen COVID-19 Research Group, Cox RJ, Langeland N. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021. 10.1038/s41591-021-01433-3. - PubMed
    1. Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France. Available at SSRN: https://ssrn.com/abstract=3932953. - PMC - PubMed

Publication types

Substances

LinkOut - more resources